BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
-2.68%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$17.3B
AUM Growth
+$17.3B
(-6%)
Cap. Flow
-$226M
Cap. Flow
% of AUM
-1.31%
Top 10 Holdings %
Top 10 Hldgs %
87.61%
Holding
112
New
6
Increased
21
Reduced
12
Closed
5
Top Buys
| 1 |
Roivant Sciences
ROIV
|
$46.9M |
| 2 |
AbCellera Biologics
ABCL
|
$38.8M |
| 3 |
Kymera Therapeutics
KYMR
|
$34.4M |
| 4 |
IMGN
Immunogen Inc
IMGN
|
$28.7M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
$22.2M |
Top Sells
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$454M |
| 2 |
Krystal Biotech
KRYS
|
$15.6M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$15M |
| 4 |
FibroGen
FGEN
|
$6.48M |
| 5 |
Verastem
VSTM
|
$5.88M |
Sector Composition
| 1 | Healthcare | 99.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Nkarta
NKTX
$149M
| $594K | ﹤0.01% |
271,329
-128,671
| -32% | -$282K |
|
102
Protara Therapeutics
TARA
$125M
| $477K | ﹤0.01% |
199,671
| – | – |
|
|
GTH
103
DELISTED
Genetron Holdings Limited ADS
GTH
| $423K | ﹤0.01% |
151,769
| – | – |
|
104
Foghorn Therapeutics
FHTX
$298M
| $317K | ﹤0.01% |
45,027
| – | – |
|
|
VINC
105
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $293K | ﹤0.01% |
11,279
-790
| -7% | -$20.5K |
|
106
Surrozen, Inc. Warrant
SRZNW
$71.9K
| $46K | ﹤0.01% |
833,333
| – | – |
|
107
Atara Biotherapeutics
ATRA
$88.7M
| – | – |
-29,767
| Closed | -$2.16M |
|
|
BPMC
108
DELISTED
Blueprint Medicines
BPMC
| – | – |
-333,665
| Closed | -$15M |
|
109
Veru
VERU
$48.5M
| – | – |
-160,958
| Closed | -$1.87M |
|
|
BLCM
110
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| – | – |
-249,123
| Closed | -$82.2K |
|
|
TCRR
111
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| – | – |
-753,064
| Closed | -$1.13M |
|